MedTrace Logo

Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)

NCT00473876 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2013-06-06

Study results available
· View outcomes & findings →

Summary

Will metformin improve exercise capacity in chronic heart failure patients who has insulin resistance (pre-diabetic- means before they become diabetic)?

Conditions

Interventions

DRUG

Metformin

Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks

DRUG

Matched Placebo (Capsules)

Similar dosing regime as active comparator

Sponsors & Collaborators

  • University of Dundee

    lead OTHER

Principal Investigators

  • Chim Lang, MD, FRCP · University of Dundee, Scotland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00473876 on ClinicalTrials.gov